Anti-Human Sclerostin (SOST) (Romosozumab) – Fc Muted™ (S1015-500ug)

SOST (sclerostin) is a secreted glycoprotein that acts as a negative regulator of bone growth via inhibition of Wnt signaling1. SOST functions by blocking LRP5/6 co-receptors and binding to LRP42. SOST is expressed in the developing embryo, where it is involved in limb patterning1. Dysregulation of SOST is associated with numerous diseases including postmenopausal osteoporosis2, osteoarthritis1, ankylosing spondylitis, and rheumatoid arthritis. Mutations are also associated with inherited high bone mass conditions involving excessive bone formation, such as sclerosteosis, craniodiaphyseal dysplasia, and Van Buchem Disease2. SOST has also been observed in bone tumors and bone cancer cell lines1. Monoclonal antibodies can be used to target SOST and promote new bone formation. AMG 785 (Romosozumab) is a humanized monoclonal antibody against SOST that was developed for the treatment of osteoporosis3. Romosozumab was generated as a high-affinity PEGylated antibody fragment against SOST using the Selected Lymphocyte Antibody Method (SLAM) along with proprietary antibody fragment technologies. Scl-AbII is the murine IgG1 SOST-neutralizing parent antibody. The humanized version Scl-AbIV induces a dose-dependent increase in bone mineral density in cynomolgus monkeys4. Additionally, Romosozumab leads to increased bone mineral density in humans5,6,7,8.